← Back to Search

Telehealth Services for Cancer Care in Rural Areas (ENCORE Trial)

N/A
Recruiting
Led By Debra Friedman, MD
Research Sponsored by Debra Friedman
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
- At least 21 years of age or older and English speaking with the ability to provide informed consent
Newly diagnosed or relapsed cancer patients of aforementioned oncology providers
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 3 years
Awards & highlights

ENCORE Trial Summary

This trial seeks to improve cancer care delivery to rural patients by using telehealth to connect them to the Vanderbilt-Ingram Cancer Center.

Who is the study for?
This trial is for English-speaking adults aged 21 or older who can consent to participate. It includes oncology providers within certain practices and their newly diagnosed or relapsed cancer patients. Both the provider and patient must be part of the study.Check my eligibility
What is being tested?
The trial tests a multi-level remote intervention using telehealth services, interviews, and educational materials aimed at enhancing cancer care for rural residents with limited access to comprehensive treatment facilities.See study design
What are the potential side effects?
Since this trial involves non-invasive interventions like telehealth services, interviews, and educational materials rather than medications or medical procedures, traditional side effects are not expected.

ENCORE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 21 or older, speak English, and can give informed consent.
Select...
I have been recently diagnosed or my cancer has returned.

ENCORE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Estimate the barriers to a future large-scale multi-level intervention
Estimate the facilitators to a future large-scale multi-level intervention
Measure the effectiveness of a multi-level telehealth-based intervention

ENCORE Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: CTS Program ArmExperimental Treatment2 Interventions
6-week intervention delivered via telehealth using the VUMC telehealth services.
Group II: Education Attention Control ArmActive Control1 Intervention
Receive educational materials either online, by email, or in print form.

Find a Location

Who is running the clinical trial?

Debra FriedmanLead Sponsor
1 Previous Clinical Trials
33 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,627 Previous Clinical Trials
40,926,647 Total Patients Enrolled
Debra Friedman, MD5.01 ReviewsPrincipal Investigator - Vanderbilt-Ingram Cancer Center
Vanderbilt-Ingram Cancer Center
3 Previous Clinical Trials
961 Total Patients Enrolled

Media Library

VUMC telehealth services Clinical Trial Eligibility Overview. Trial Name: NCT04758338 — N/A
Cancer Research Study Groups: CTS Program Arm, Education Attention Control Arm
Cancer Clinical Trial 2023: VUMC telehealth services Highlights & Side Effects. Trial Name: NCT04758338 — N/A
VUMC telehealth services 2023 Treatment Timeline for Medical Study. Trial Name: NCT04758338 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many healthcare centers have implemented this research project?

"The current trial is running in 5 distinct sites, including Oxford and Nashville. To alleviate the need for extensive travel, participants may want to consider selecting a medical centre closest to their home or place of residence."

Answered by AI

What is the aggregate number of participants involved in this experiment?

"Correct. Clinicaltrials.gov confirms that this trial, which was originally published on October 25th 2021, is currently recruiting patients. Approximately 700 participants need to be sourced from 5 diverse medical facilities."

Answered by AI

Are there still slots available for individuals to partake in this clinical trial?

"Absolutely. According to clinicaltrials.gov, the trial is currently open for enrollment with a posting date of October 25th 2021 and an update on November 15th 2022. During this period, 700 participants are needed at 5 separate locations."

Answered by AI
~467 spots leftby Dec 2030